Updated: Novo Holdings pays $16.5B to take Catalent private — and sells three manufacturing sites to Novo Nordisk
Novo Holdings, the investment arm of Novo Nordisk’s parent foundation, is buying Catalent in a deal valued at $16.5 billion, the biggest it’s ever made.
Catalent, a major player in the contract development and manufacturing world, is heavily involved in producing Novo Nordisk’s top-selling obesity drug Wegovy, which continues to be in shortage. As part of the all-cash deal, Novo Holdings will sell three Catalent fill-finish sites and related assets to Novo Nordisk in Italy, Belgium and Bloomington, IN.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.